Product Images Apo-varenicline

This is a set of instructions for taking medication called APO-Varenicline for the first seven days. The medication comes in the form of 0.5 mg tablets that are white in color. On day 1 to 3, you should take one tablet per day. On day 4 to 7, you should take one tablet in the morning and one tablet in the evening, at the same time each day.*

This text provides instructions for taking medication called APO-Varenicline twice a day for a specified duration. It advises taking one white pill of 0.5 mg in the morning and one in the evening at approximately the same time each day. The duration of the treatment is until Day 8, after which the medication should be stopped.*

This text provides instructions for taking varenicline for the treatment of an unknown condition. The recommended dose is 1 mg twice a day, taken in the morning and evening at approximately the same time each day. The medication is a light blue pill with the label "APO-Varenicline." The treatment course can span several days with the last day being Day 8.*

This appears to be a medical report on the effects of a medication called Vareaicing compared to a placebo. The report describes the symptoms of participants who took the medication versus those who took the placebo in various system organ categories. It mentions symptoms like dyspepsia, gasmosophageal disease, dry mouth, headaches, and abnormal dreams. One group taking the medication experienced fewer symptoms than the placebo group. The report also includes a table with dosage information and the number of participants who experienced certain symptoms.*

Table data on Treatment Emergent Cardiovascular Events that occurred within 30 days of the first dose and were observed in a certain number of participants in a specific treatment group. No further information is available as the text is incomplete.*

The text provides results of clinical trials of smoking cessation therapies on two cohorts - Non-psychiatric and Psychiatric with the number of patients treated, composite NPS AE primary endpoint, and RD (Risk Difference) with 95% confidence interval. Varenicline, Bupropion, and NRT (Nicotine Replacement Therapy) were used as therapies, while Placebo was used as a control.*

This text presents data on the incidence of psychiatric and non-psychiatric adverse events caused by the medications Varenicline, Bupropion, NRT, and Placebo. The percentage of patients with psychiatric adverse events was higher than non-psychiatric adverse events in all treatment groups. The report also categorizes adverse events by disorder and symptom, including anxiety, depressed mood, and sleep disturbances.*

This is a prescription drug called Chantix (varenicline) manufactured by Pfizer Labs. Each tablet contains 0.85 mg varenicline tartrate equivalent to 0.5mg varenicline free base to help people quit smoking. It should be stored at 26°C (77°F) and in tight, child-resistant containers. Excursions are permitted between the temperatures of 15-30°C (69-86°F). Dispensing should be done in accordance with the accompanying prescribing information guide. The drug has an NDC number 0069-0468-56 and is only available on a prescription basis.*

This text provides instructions and information about Chantix® (varenicline) tablets, including recommended storage temperatures and container requirements. It also notes the dosage information and that each tablet contains 1.71mg varenicline tartrate equivalent to 1mg varenicline free base. The text is distributed by Pfizer Labs and made in Ireland. The National Drug Code for Chantix tablets is 0069-0469-56. The text suggests that medication guide always be dispensed with the tablets.*

This appears to be information about a medication called APO-VARENICLINE, used in smoking cessation treatment for adults in conjunction with counseling. Each tablet contains 0.5 mg of varenicline under the form of tartrate. The dosage, as well as other information, is available in the product monograph. The tablet should be taken after meals, with a large glass of water. The text also lists the medication's excipients and coating components. There is no clear context or purpose for the first part of the text, which is only a jumble of letters and numbers.*

This is a dosing regimen for a medication starting with a dose of 0.5mg twice daily for the first three days followed by an increase to 0.5mg once daily for days four to seven. On day eight and onwards, the dose is increased to 0.5mg twice daily and then 1mg twice daily.*

This appears to be a chart showing the results of a study comparing the effectiveness of Chantix (a medication used to help people quit smoking) versus a placebo. The chart shows the percentage of continuous abstinence from smoking over a period of 52 weeks. The participants in the study were followed up with for varying amounts of time, stated in weeks.*

This text appears to be describing various negative symptoms that are commonly associated with nicotine withdrawal. These symptoms include an urge to smoke, frustration, restlessness, depressed mood, anger, decreased heart rate, trouble sleeping, anxiety, increased appetite, irritability, difficulty concentrating, and weight gain.*

This text appears to be describing some symptoms of an allergic reaction, such as swelling of the face, mouth, throat, or neck, as well as trouble breathing. Additionally, it mentions a rash with peeling skin and blisters in the mouth. It is important to seek medical attention immediately if experiencing any of these symptoms.*

This text outlines a smoking reduction plan spanning over 12 weeks. The plan involves reducing the number of cigarettes smoked from the starting daily number to half the amount during weeks 1 through 4, then further down to a quarter of the starting daily number in weeks 5 through 8. The goal is to continue reducing the smoking until eventually reaching zero cigarettes per day by week 12.*

This text provides a medication regimen for a treatment that involves taking white tablets (0.5 mg) for the first three days, followed by taking one tablet per day; taking white tablets (0.5 mg) from day 4 to day 7, with one tablet in the morning and one in the evening; and taking blue tablets (1 mg) from day 8 until the end of treatment, with one tablet in the morning and one in the evening.*

The text seems to describe the effects of alcohol intoxication, including increased drunkenness, unusual or aggressive behavior, and memory lapses.*

This text describes the different pack sizes and their respective National Drug Codes (NDC) for a medication. There are starting and continuing 4-week cards with different amounts of tablets, a starting and continuing month box, and bottles of 0.5 mg and 1 mg with a quantity of 56 tablets each, each with their own unique NDC.*

This appears to be numeric data comparing the effectiveness of CHANTIX versus Placebo in a COPD Study over a period of 12 weeks. It shows the percentage of participants who used CHANTIX and Placebo twice daily and the corresponding percentage of them who quit smoking.*

This is a table showing the results of a study conducted over 52 weeks with a drug called Chantix compared to placebo. The study was done on patients with cardiovascular disease. The data shows the percentage of patients who experienced certain effects while taking 1mg of Chantix twice a day compared to those on placebo. The study was conducted from weeks 9 to 12 and then continued until week 52.*

This text seems to be presenting data related to the impact of the drug CHANTIX on mortality and cardiovascular events. It includes numbers for nonfatal myocardial infarctions, strokes, peripheral vascular disease procedures, hospitalizations for angina pectoris and transient ischemia attacks, and the need for coronary revascularization, among others. The data is presented for up to 52 weeks after treatment with CHANTIX, as well as for a period of time beyond 30 days after treatment.*

The text describes a comparison between the drug Chantix and a placebo in terms of MACE cases. The data shows that out of 4190 patients taking Chantix, 13 had MACE cases (0.31%), while out of 2812 patients taking the placebo, 6 had MACE cases (0.21%). The Hazard Ratio (95% CI) is 1.95 (0.79, 4.82), and the Rate Difference per 1,000 patient-years (95% CI) is 630 (-2.40,15.10). The study included MACE occurring up to 30 days post-treatment.*

This is a statistical table comparing the results of a MDD (Major Depressive Disorder) study between the Chantix drug and placebo. The study involved weeks 9 through 12 and weeks 9 through 52. Chantix was administered twice a day at a dose of 1 mg. The table includes percentages of patients experiencing MDD on Chantix and placebo, with further breakdowns of the ranges of these percentages.*

This appears to be a table or data from a study involving two medications, CHANTIX and Bupropion, with a sample size of 968 participants. The table lists the number and percentage of participants who experienced clinically significant non-psychiatric adverse events and serious non-psychiatric adverse events. It also indicates the number of participants who required psychiatric hospitalization. Without further context or information, it is unclear what the specific adverse events or psychiatric hospitalizations were related to.*

The text appears to be a table that compares the incidence of clinically significant non-psychiatric symptoms (NPS), serious NPS, and psychiatric hospitalizations in two treatment groups: CHANTIX and Bupropion. The table displays the number of patients (N) in each group and the percentage of patients who experienced each type of symptom. There is not enough information to determine the purpose of the study or the context in which the data was collected.*

The given text seems to be presenting the percentages of individuals in different cohorts who took different medications (CHANTIX, Bupropion SR, NRT, Placebo) and had Non-Psychiatric or Psychiatric adverse reactions in weeks 9 through 12 and weeks 9 through 24. The medications were taken twice daily in certain dosages.*

This is a study involving Chantix and bupropion conducted in 2006 with 1997 participants. The study evaluates the incidence rate of MACE (major adverse cardiovascular events) during treatment and through the end of the study. The Hazard Ratio (95% CI) of the treatment group versus placebo is shown. The study includes a parent neuropsychiatric safety study and an extension study. [IR] indicates incidence rate per 1000 person-years.*

This is a safety study comparison of two drugs, Chantix and Bupropion Placebo. The study involved 1997 participants for Chantix and 2007 participants for Bupropion Placebo. The study analyzed the incidence rate per 1000 person-years of Major Adverse Cardiovascular Events (MACE) and all-cause deaths during treatment and through the end of the study. The study used the abbreviation IR to indicate the incidence rate per 1000 person-years.*

The text contains a table with adverse events reported in two treatment groups. The events include angina pectoris, chest pain, peripheral edema, hypertension, palpitations, and cardiovascular mortality. Nonfatal serious cardiovascular events are also included such as nonfatal MI, hospitalization for angina pectoris, need for coronary revascularization, and new diagnosis of peripheral vascular disease. The data is categorized in timeframes such as up to 30 days after treatment and up to 57 weeks after treatment.*

This is a description of a study comparing the effects of Chantix and a placebo on individuals. It appears that Chantix may have caused more adverse events, including nausea, headaches, and vomiting. Additionally, psychiatric adverse events occurred at a higher rate in the Chantix group compared to the placebo group. The measured medication dosage was Lmg BID, and the study involved Nos4 Net3 individuals. The meaning behind "Tusommia 0 5" is not available.*

The text provides information on adverse events experienced by a treatment group, with a significant increase in the incidence of adverse events (210%). The adverse events reported include nausea, headache, abnormal dreams, insomnia, and irritability. Additionally, there were psychiatric adverse events reported in both treatment groups which include depressed mood disorders and disturbances, anxiety, agitation, tension, hostility, and restlessness.*

The text describes adverse events in a study population for varenicline treatment, including nausea, headache, and psychiatric adverse events. It also reports on non-psychiatric and psychiatric cohorts with symptoms such as abnormal dreams, anxiety, and depression.*

This is a comparison of the effectiveness of CHANTIX and Bupropion SR. There are different studies shown, and the percentages of effectiveness for each medication are provided. The effectiveness is related to placebo and measured in different dosages. However, at the end of the text, there are unreadable characters, possibly due to an error.*

The text describes the results of a study for the drug CHANTIX compared to a placebo during weeks 9 to 12 and weeks 9 to 52. It also mentions the dosing of 1 mg twice daily (BID). The percentages represent rates of retreatment for CHANTIX and placebo.*

Daysi-3 is a prescription drug that requires taking 0.5 mg twice daily. The duration of treatment is not specified. On day 5, the dosage changes to once daily. The text also mentions "T g twace datly," which is unclear and may be a transcription error.*

This is a description of a smoking-cessation aid medication called APO-VARENICLINE. Each tablet contains 1 mg of varenicine and is meant for use in adults as part of a smoking-cessation counseling program. The usual adult dose should be taken after eating and with a full glass of water. The tablets come with a Consumer Information Leaflet that should be dispensed by a pharmacist. The tablets contain some non-medicinal ingredients and also include indigotie Al lake 12-14% as a colorant. The text also includes phone numbers for customer questions and concerns.*

This text provides information about the distributing company, Pfizer Labs, which is a division of Pfizer Inc, located in NY, NY 10017. It includes a code number "LAB-0328-16.1".*